

**LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)**  
**RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES**

(amounts in thousands)  
(unaudited)

Reconciliation between GAAP and Non-GAAP sales growth:

For the three months ended March 31, 2026

Net direct sales as reported	\$ 63,861	
Impact of currency exchange rate fluctuations on direct sales	<u>(1,976)</u>	
Adjusted net sales		\$ 61,885

For the three months ended March 31, 2025

Net direct sales as reported	\$ 56,272	
Net impact of divestitures excluding currency on direct sales	<u>(1,475)</u>	
Adjusted net sales		<u>\$ 54,797</u>

Adjusted net direct sales increase for the three months ended March 31, 2026 \$ 7,088 13%

Reconciliation between GAAP and Non-GAAP patches sales growth:

For the three months ended March 31, 2026

Net sales as reported	\$ 12,557	
Impact of currency exchange rate fluctuations	<u>(467)</u>	
Adjusted net sales		\$ 12,090

For the three months ended ended March 31, 2025

Net sales as reported	\$ 13,298	
Net impact of divestitures excluding currency on direct sales	<u>(1,475)</u>	
Adjusted net sales		<u>\$ 11,823</u>

Adjusted patches net sales increase for the three months ended March 31, 2026 \$ 267 2%